| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Martyn D Greenacre is Director at LSTA, with reported holdings spanning 2 companies. Martyn D Greenacre's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $115K at current prices.
Martyn D Greenacre's largest disclosed position is in LSTA as Director, worth about $96K.
Martyn D Greenacre has 18 Form 4 filings on record from January 2015 to July 2026, across 2 companies: Director at Curis (CRIS), 2015–2026; Director at Lisata Therapeutics (LSTA), 2015.
The 23 reported transactions were 12 option or other derivative awards, 4 option exercises, 3 open-market sales and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $45K.
The largest open-market sale was 15,000 shares of CRIS at an average $1.69 on May 27, 2016, about $25K.